Antibodies that develop following an initial infection with a type of HSV prevents reinfection with the same virus type—a person with a history of orofacial infection caused by HSV-1 cannot contract herpes whitlow or a genital infection caused by HSV-1. [ citation needed ] In a monogamous couple, a seronegative female runs a greater than 30% per year risk of contracting an HSV infection from a seropositive male partner.  If an oral HSV-1 infection is contracted first, seroconversion will have occurred after 6 weeks to provide protective antibodies against a future genital HSV-1 infection. Herpes simplex is a double-stranded DNA virus . 
Not only can herpes be spread if there is no sore, MOST herpes is transmitted in the absence of lesions! It is now estimated that over 80% of all genital herpes is transmitted when there isn't anything on the skin and no symptoms. Patients have been aware for many years that if they kissed someone while having a fever blister or had sex with their partner while having an outbreak of genital herpes that they were likely to transmit the virus. Despite this knowledge, however, a 30% increase in the prevalence of HSV 2 infections was documented in the 1980s and 1990s. This increase is most likely due to the presence of HSV on the genital skin in the absence of lesions or symptoms. This phenomenon is known as "asymptomatic viral shedding" and has been demonstrated in well-controlled clinical investigations. Most recently, persons who never recall having had an outbreak of genital herpes, but who have had positive blood tests for antibodies to herpes, also have been demonstrated to "shed" the virus occasionally from lips or genital skin. It has been demonstrated that persons who take acyclovir daily have reduced amounts of the virus in the absence of symptoms or lesions. The same is probably true of the newer drugs, famciclovir and valacyclovir. It is logical that taking one of these three drugs everyday would reduce the chances of passing the virus to an uninfected partner, but this has not yet been proven.
Globally it is estimated that there are 1,000,000 new cases and 9,000,000 recurrent episodes of ocular HSV each year. It is also estimated that ocular HSV is responsible for visual disability in 1,000,000 people world-wide each year. 31, 32 In the United States, patients make an average of four visits to an ophthalmologist for the first episode and six visits for recurring episodes of ocular HSV. 18 It is estimated that a doctor’s visit for ocular HSV results in a loss of one full day of work or leisure per visit. 33 Based on this data and estimates of incidence in the ., 19 an estimated 58 million days of work (444,000 in the .) are lost treating ocular HSV worldwide each year. In addition, there is a significant burden attributed to the disease itself. The mean time from onset of symptoms to resolution of active ocular HSV disease was estimated at days for the first episode and days for recurrent episodes. 18